4.7 Article

Procalcitonin as a Biomarker in Respiratory Tract Infection

期刊

CLINICAL INFECTIOUS DISEASES
卷 52, 期 -, 页码 S346-S350

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir050

关键词

-

资金

  1. Food and Drug Administration
  2. Infectious Diseases Society of America
  3. AstraZeneca Pharmaceuticals
  4. Bio Merieux, Inc.
  5. Cepheid
  6. Gilead Sciences
  7. Intelligent MDX, Inc.
  8. Inverness Medical Innovations
  9. Roche Molecular Systems

向作者/读者索取更多资源

Serum procalcitonin (PCT) levels rapidly increase in patients with invasive bacterial disease. PCT levels increase faster than do C-reactive protein levels. Furthermore, a rapid decrease in the PCT level is supporting evidence that the source of the bacterial infection is responding to clinical management. In patients with community-acquired bacterial pneumonia, sequential PCT levels are useful as a guide to shorter courses of antimicrobial therapy. With use of emerging multiplex real-time polymerase chain reaction platforms for the detection of viral and bacterial respiratory pathogens, it should be possible to critically assess whether an elevated serum PCT level is a valid biomarker of invasive bacterial infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据